Trials / Completed
CompletedNCT00679510
Rosuvastatin in Rheumatoid Arthritis (RORA)
Phase 2: Effects of Rosuvastatin on Surrogate Markers for Cardiovascular Events in Patients With Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- University of Dundee · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
Patients with rheumatoid arthritis are at increased risk of having cardiovascular deaths. The investigator's study is aimed at looking at the effects of proven cholesterol lowering treatment drug called rosuvastatin in rheumatoid arthritis patients on few cardiovascular markers. Endothelial behaviour improved on treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rosuvastatin | tablet 10 mgs once daily |
| DRUG | placebo | placebo |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2008-01-01
- Completion
- 2008-01-01
- First posted
- 2008-05-19
- Last updated
- 2019-11-05
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00679510. Inclusion in this directory is not an endorsement.